Exact Mass: 319.2147324
Exact Mass Matches: 319.2147324
Found 265 metabolites which its exact mass value is equals to given mass value 319.2147324,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Chloroquine
Chloroquine is only found in individuals that have used or taken this drug. It is a prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. [PubChem]The mechanism of plasmodicidal action of chloroquine is not completely certain. Like other quinoline derivatives, it is thought to inhibit heme polymerase activity. This results in accumulation of free heme, which is toxic to the parasites. nside red blood cells, the malarial parasite must degrade hemoglobin to acquire essential amino acids, which the parasite requires to construct its own protein and for energy metabolism. Digestion is carried out in a vacuole of the parasite cell.During this process, the parasite produces the toxic and soluble molecule heme. The heme moiety consists of a porphyrin ring called Fe(II)-protoporphyrin IX (FP). To avoid destruction by this molecule, the parasite biocrystallizes heme to form hemozoin, a non-toxic molecule. Hemozoin collects in the digestive vacuole as insoluble crystals.Chloroquine enters the red blood cell, inhabiting parasite cell, and digestive vacuole by simple diffusion. Chloroquine then becomes protonated (to CQ2+), as the digestive vacuole is known to be acidic (pH 4.7); chloroquine then cannot leave by diffusion. Chloroquine caps hemozoin molecules to prevent further biocrystallization of heme, thus leading to heme buildup. Chloroquine binds to heme (or FP) to form what is known as the FP-Chloroquine complex; this complex is highly toxic to the cell and disrupts membrane function. Action of the toxic FP-Chloroquine and FP results in cell lysis and ultimately parasite cell autodigestion. In essence, the parasite cell drowns in its own metabolic products. P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01B - Antimalarials > P01BA - Aminoquinolines COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
1-Carbazol-9-yl-3-(3,5-dimethylpyrazol-1-yl)-propan-2-ol
2-[2-[[4-[[3-Aminopropyl]amino]butyl]amino]-2-oxoethyl]-2-hydroxybutanedioic acid
Homocapsaicin
Isolated from the pungent principle of red pepper (Capsicum annuum). Homocapsaicin is found in many foods, some of which are green bell pepper, pepper (c. annuum), herbs and spices, and italian sweet red pepper. Homocapsaicin is found in herbs and spices. Homocapsaicin is isolated from the pungent principle of red pepper (Capsicum annuum
Latrepirdine
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Latrepirdine is a tricyclic H1-antihistamine.
b-Dihydrotetrabenazine
b-Dihydrotetrabenazine is a metabolite of tetrabenazine. Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntingtons disease (HD), the first in the US. The compound has been known since the 1950s. (Wikipedia)
alpha-dihydrotetrabenazine
alpha-dihydrotetrabenazine is a metabolite of tetrabenazine. Tetrabenazine is a drug for the symptomatic treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman in Canada and Xenazine in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. On August 15, 2008 the U.S. Food and Drug Administration (FDA) approved the use of tetrabenazine to treat chorea associated with Huntingtons disease (HD), the first in the US. The compound has been known since the 1950s. (Wikipedia)
6-Acetyloxy-3,4-dihydro-N,N,2,5,7,8-hexamethyl-2H-1-benzopyran-2-ethanamine
Deshydroxyethyl opipramol
Imidafenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Imidafenacin (KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors.
Pentisomide
C19H33N3O (319.26234880000004)
D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea
17α-Methyl-androstan-3-hydroxyimine-17β-ol
C20H33NO2 (319.25111580000004)
9-(4-aminophenyl)-7-hydroxy-2,4,6-trimethyl-9-oxonon-2-enoic acid
(S)-2-[(2-Methyl-1-oxopropyl)amino]-N-(2-phenylethyl)pentanediamide
(2S,4S,10R)-4-(3-hydroxy-4-methoxyphenyl)-quinolizidin-2-acetate
9-(4-aminophenyl)-3,7-O-cyclo-2,4,6-trimethyl-9-oxo-nonanoic acid
(-)-Pictamine|(3R,4S,6S,9aS)-4-methyl-6-((1E,3E)-deca-1,3-dienyl)-octahydro-quinolizin-3-yl acetate|Pictamine
C20H33NO2 (319.25111580000004)
(E)-N-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-decenamide|homocapsaicin|Homocapsaicin II|homocapsaicin-II
HomocapsaicinII
Homocapsaicin II is a natural product found in Capsicum annuum with data available.
chloroquine
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01B - Antimalarials > P01BA - Aminoquinolines COVID info from Guide to PHARMACOLOGY, DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent D018501 - Antirheumatic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
(7R,E)-8-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-en-2-one
C20H33NO2 (319.25111580000004)
(7R,E)-8-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-3-en-2-one
C20H33NO2 (319.25111580000004)
(7R,E)-8-((1S,Z)-1-hydroxy-1-methylhexahydro-2H-quinolizin-3(4H)-ylidene)-4,7-dimethyloct-4-en-3-one
C20H33NO2 (319.25111580000004)
N-hydroxy arachidonoyl amine
C20H33NO2 (319.25111580000004)
Anandamide (18:4, n-3)
C20H33NO2 (319.25111580000004)
1-[(tert-butyl)oxycarbonyl]-3-benzylpiperidine-3-carboxylic acid
1-(2-METHOXY-PHENYL)-PYRROLE-2,5-DIONE
C20H30ClN (319.20666500000004)
3-N-BOC-AMINO-1-(2-AMINO-1-M-TOLYL-ETHYL)-PYRROLIDINE
TERT-BUTYL 2-(4-(METHOXYCARBONYL)-2-METHYLPHENYL)PYRROLIDINE-1-CARBOXYLATE
4-BENZYL-1-(TERT-BUTOXYCARBONYL)PIPERIDINE-4-CARBOXYLIC ACID
Myristyl nicotinate
C20H33NO2 (319.25111580000004)
C26170 - Protective Agent > C2459 - Chemoprotective Agent
butanedioic acid,1-(2-hydroxyethyl)-2,2,6,6-tetramethylpiperidin-4-ol
1-Benzyl 3-methyl 3-isopropyl-1,3-piperidinedicarboxylate
calcium 2-[[(2-aminoethyl)amino]methyl]-4-dodecylphenolate (1:2)
2-(DICYCLOHEXYLPHOSPHINOETHYL)TRIMETHYLAMMONIUM CHLORIDE
C17H35ClNP (319.2195510000001)
(3S,4R)-1-(TERT-BUTOXYCARBONYL)-4-(4-ETHYLPHENYL)PYRROLIDINE-3-CARBOXYLIC ACID
[1-(4-amino-benzoyl)-piperidin-4-yl]-carbamic acid tert-butyl ester
TERT-BUTYL 4-HYDROXYSPIRO[CHROMAN-2,4-PIPERIDINE]-1-CARBOXYLATE
tert-butyl 4-(4-formylbenzyloxy)piperidine-1-carboxylate
ethyl (E,2S)-2-(tert-butoxycarbonylamino)-5-phenyl-pent-3-enoate
Butopiprine
C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent
tert-Butyl 4-[(2-aminobenzene)amido]piperidine-1-carboxylate
Carbamic acid, N-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, 1,1-dimethylethyl ester
(2R)-2-(Hydroxymethyl)-3-(cyclopentyl)-N-(phenylmethoxy)hexanamide
1-(2-Ethylbutyl)-N-(2-sulfanylphenyl)cyclohexanecarboxamide
C19H29NOS (319.19697440000004)
1-BOC-4-[METHYL-(2-PYRIDIN-2-YL-ETHYL)-AMINO]-PIPERIDINE
N-(4-FLUORO-2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)CYCLOPENTANAMINE
Cilansetron
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03A - Drugs for functional gastrointestinal disorders > A03AE - Serotonin receptor antagonists C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist
N-[1-(benzylamino)-4-methyl-1-oxopentan-2-yl]-N-tert-butylcarbamate
1,3-Piperidinedicarboxylic acid, 3-(phenylmethyl)-, 1-(1,1-dimethylethyl) ester, (3R)-
(E)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine
(4-amino-3-methyl-phenyl)-bis(4-aminophenyl)methanol
4-(2-AMINO-PHENYLCARBAMOYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
tert-butyl 4-[(3-aminophenyl)carbamoyl]piperidine-1-carboxylate
4-(4-AMINO-PHENYLCARBAMOYL)-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
[1-(3-AMINO-BENZOYL)-PIPERIDIN-4-YL]-CARBAMIC ACID TERT-BUTYL ESTER
4-CARBOXYMETHYL-4-PHENYL-PIPERIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
Tert-butyl-n-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]carbamate
tert-butyl 4-[3-[(methylamino)methyl]benzyl]tetrahydro-1(2h)-pyrazinecarboxylate
1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea
D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D004791 - Enzyme Inhibitors
Tesmilifene hydrochloride
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists C308 - Immunotherapeutic Agent > C210 - Immunoadjuvant > C2141 - Chemo Immunostimulant Adjuvant C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist C1892 - Chemopreventive Agent C2140 - Adjuvant
Dalcotidine
C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29702 - Histamine-2 Receptor Antagonist
(2S,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizin-2-ol
[1-(3-Methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone
N-{[(3,5-Di-tert-butyl-4-hydroxyphenyl)methoxy]methyl}prop-2-enamide
Imidafenacin
G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BD - Drugs for urinary frequency and incontinence C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Imidafenacin (KRP-197; ONO-8025) is a potent and selective inhibitor of M3 receptors.
(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoate
15(R)-Hete(1-)
A 15-HETE(1-) that is the conjugate base of 15(R)-HETE(1-), obtained by deprotonation of the carboxy group; major species at pH 7.3.
Trimethyl-[2-methyl-4-[oxo(1-piperidinyl)methoxy]-5-propan-2-ylphenyl]ammonium
C19H31N2O2+ (319.23854059999996)
5(S)-Hete(1-)
An icosanoid anion that is the conjugate base of 5(S)-HETE, obtained by deprotonation of the hydroxy group; major species at pH 7.3.
12(R)-Hete(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 12(R)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
12(S)-Hete(1-)
An icosanoid anion that is the conjugate base of 12(S)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoate
4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoate
(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoate
(Z)-N-(cyclopropylmethyl)-N-methyl-3,6-diphenylhex-5-en-3-amine
(2S)-2-cyano-1-(4-phenyl-L-phenylalanyl)pyrrolidine
18(R)-Hete(1-)
A 18-HETE(1-) that is the conjugate base of 18(R)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
Leu-Thr-Ser
A tripeptide composed of L-leucine, L-threonine and L-serine joined in sequence by peptide linkages.
Ethyl 4-(2-benzamidoethylamino)piperidine-1-carboxylate
(14S,15R)-Eet(1-)
A 14,15-EET(1-) that is the conjugate base of (14S,15R)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,9E,11Z,14Z)-8-hydroxyicosa-5,9,11,14-tetraenoate
(5Z,8Z,10E,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoate
11(R)-Hete(1-)
An 11-HETE(1-) that is the conjugate base of 11(R)-HETE(1-), obtained by deprotonation of the carboxy group; major species at pH 7.3.
(8S,9R)-Eet(1-)
An 8,9-EET(1-) that is the conjugate base of (8S,9R)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(8R,9S)-Eet(1-)
An 8,9-EET(1-) that is the conjugate base of (8R,9S)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(14R,15S)-Eet(1-)
A 14,15-EET(1-) that is the conjugate base of (14R,15S)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(11S,12R)-Eet(1-)
An 11,12-EET(1-) that is the conjugate base of (11S,12R)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(11R,12S)-Eet(1-)
An 11,12-EET(1-) that is the conjugate base of (11R,12S)-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
N-[2-(1-cyclohexenyl)ethyl]-1-phenyl-4-pyrazolo[3,4-d]pyrimidinamine
(5Z,8Z,11Z,13E)-15-Hete(1-)
An icosanoid anion that is the conjugate base of 15-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-methyl-N-[4-(4-morpholinyl)phenyl]-2-quinolinimine
(5Z,8Z,11Z,14Z,16S)-16-hydroxyeicosa-5,8,11,14-tetraenoate
13(S)-Hete(1-)
A 13-HETE anion that is the conjugate base of 13(S)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8Z,11Z,14Z)-10-hydroxyicosa-5,8,11,14-tetraenoate
(3Z)-3-[(2E,4E,6E)-1-hydroxydodeca-2,4,6-trien-1-ylidene]-5-(hydroxymethyl)-1-methylpyrrolidine-2,4-dione
(5Z,8Z,11Z,14Z,16R)-16-Hydroxyeicosa-5,8,11,14-tetraenoate
17alpha-Methyl-androstan-3-hydroxyimine-17beta-ol
C20H33NO2 (319.25111580000004)
N-[2-(3,4-diethoxyphenyl)ethyl]cyclohexanecarboxamide
(1S,9R,10R,11R)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
(1R,9S,10S,11S)-10-(hydroxymethyl)-N,N-dimethyl-6-oxo-12-propyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-diene-11-carboxamide
8(S)-Hete(1-)
An icosanoid anion that is the conjugate base of 8(S)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
(5Z,8Z,12E,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoate
(2E,6E,10E,14E)-omega-hydroxygeranylgeranate
A polyunsaturated fatty acid anion resulting from the removal of a proton from the carboxy group of (2E,6E,10E,14E)-omega-hydroxygeranylgeranic acid; major species at pH 7.3.
(E)-1-(3,5-dimethylpiperidin-1-yl)-2,3-diphenylprop-2-en-1-one
(5Z,8Z,11S,12E,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoate
(3R)-9-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate
(3R,8R)-8-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxynonanoate
(5Z,7E,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoate
N-(2-Propenoxybenzylidene)bis(trimethylsilyl)methylamine
2,8-Dimethyl-5-(2-(6-methyl-3-pyridyl)ethyl)-1,2,3,4-tetrahydro-gamma-carboline
15(S)-HETE(1-)
A polyunsaturated hydroxy fatty acid anion that is the conjugate base of 15(S)-HETE.
11,12-EET(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 11,12-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
20-HETE(1-)
An omega-hydroxy fatty acid anion that is the conjugate base of omega-hydroxyarachdonic acid (20-HETE), obtained by deprotonation of the carboxy group; major species at pH 7.3.
8,9-EET(1-)
An icosanoid anion that is the conjugate base of 8,9-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
5,6-EET(1-)
An EET(1-) that is the conjugate base of 5,6-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
18-HETE(1-)
A hydroxy fatty acid anion that is the conjugate base of 18-hydroxyarachidonic acid, arising from deprotonation of the carboxy group; major species at pH 7.3.
N-(6Z,9Z,12Z,15Z-octadecatetraenoyl)-ethanolamine
C20H33NO2 (319.25111580000004)
12-HETE(1-)
An icosanoid anion that is the conjugate base of 12-HETE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
11-HETE(1-)
An icosanoid anion that is the conjugate base of 11-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
11(S)-HETE(1-)
An 11-HETE(1-) that is the conjugate base of 11(S)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
9-HETE(1-)
A HETE anion that is the conjugate base of 9-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
5-oxo-ETrE(1-)
An icosanoid anion that is the conjugate base of (6E,8Z,11Z)-5-oxoicosatrienoic acid (5-oxo-ETrE), obtained by deprotonation of the carboxy group; major species at pH 7.3.
8-HETE(1-)
An icosanoid anion that is the conjugate base of 8-HETE arising from deprotonation of the carboxylic acid function; major species at pH 7.3.
5-HETE(1-)
An unsaturated fatty acid anion that is the conjugate base of 5-hydroxy-6E,8Z,11Z,14Z-icosatetraenoic acid, obtained by deprotonation of the carboxy group.
19-HETE(1-)
A polyunsaturated fatty acid anion that is the conjugate base of 19-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
16(R)-HETE(1-)
A 16-HETE(1-) that is the conjugate base of 16(R)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
16(S)-HETE(1-)
A 16-HETE(1-) that is the conjugate base of 16(S)-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
7-HETE(1-)
A HETE anion that is the conjugate base of 7-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
13-HETE(1-)
A HETE anion that is the conjugate base of 13-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
10-HETE(1-)
A HETE anion that is the conjugate base of 10-HETE, obtained by deprotonation of the carboxy group; major species at pH 7.3.
14,15-EET(1-)
An icosanoid anion that is the conjugate base of 14,15-EET, obtained by deprotonation of the carboxy group; major species at pH 7.3.
pyranonigrin I
A member of the class of pyrrolidin-2-ones with formula C18H25NO4, originally isolated from Aspergillus niger.
1-Carbazol-9-yl-3-(3,5-dimethyl-pyrazol-1-yl)-propan-2-ol
(4e)-7-(chloromethylidene)-n-(2-phenylethyl)dec-4-enimidic acid
(2e)-9-(4-aminophenyl)-7-hydroxy-2,4,6-trimethyl-9-oxonon-2-enoic acid
2-ethyl-1-{[(6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl)(hydroxy)methylidene]amino}cyclopropane-1-carboxylic acid
(1s,2s)-1-({[(3as,6r,7as)-6-ethyl-1-oxo-2,3,3a,6,7,7a-hexahydroinden-4-yl](hydroxy)methylidene}amino)-2-ethylcyclopropane-1-carboxylic acid
(3r,4s,6s,9as)-4-methyl-6-[(1e,3e)-octa-1,3-dien-1-yl]-octahydro-1h-quinolizin-3-yl acetate
C20H33NO2 (319.25111580000004)